Vaccination ecosystem health check: achieving impact today and sustainability for tomorrow

Mitra Saadatian-Elahi1*, David Bloom2, Stanley Plotkin3, Valentina Picot4, Jacques Louis4 and Michael Watson5

Abstract

Background: Vaccination is a complex ecosystem with several components that interact with one another and with the environment. Today’s vaccine ecosystem is defined by the pursuit of polio eradication, the drive to get as many of the new vaccines to as many people as possible and the research and development against immunologically challenging diseases. Despite these successes, vaccine ecosystem is facing key issues with regard to supply/distribution and cost/profitability asymmetry that risk slowing its global growth.

Main findings: Small and decreasing numbers of suppliers/manufacturing facilities; paucity of research-driven companies; regulatory pressures; market uncertainties; political prioritization; anti-vaccine movements/complacency; and technological and programmatic issues were acknowledged as the major challenges that could weaken today’s vaccination ecosystem.

Keywords: Conference report, Vaccination ecosystem, Vaccine demand and supply, Vaccine research and development

Introduction

Vaccination comprises a complex ecosystem similar to natural ecosystems; it can be represented as an organism-community of international organizations, vaccine manufacturers, donor agencies, foundations, nongovernmental organisms, etc. that interact with one another and with the environment. As a consequence, modifications or variations in one of its components can affect the ecosystem balance.

National immunization programs together with Gavi, the Vaccine Alliance (Gavi), international aid, philanthropic donors, tiered pricing by large research and development (R&D) vaccine manufacturers, and the availability of generic vaccines have significantly decreased vaccine access gaps between high- and low-income countries by improving vaccination of the world’s poorest children. However, this success should not prevent continuous examination of whether we are fully optimizing the huge untapped potential of today’s vaccines without damaging the benefit that future vaccination innovation can bring.

Today’s vaccine ecosystem is defined by the pursuit of polio eradication, the drive to get as many of the new vaccines to as many people as possible and the R&D pursuit of vaccines against immunologically challenging diseases such as HIV, Malaria, TB, Dengue, RSV, HSV, Chlamydia and others. This era is also characterized by the emergence of major private donors and government
subsidies. These donors and their agencies aim to extend global access to all vaccines through «push and pull» innovation in vaccines and vaccines systems. To achieve this they implement “market-shaping” aimed at incentivizing increased volumes, lower prices and new producers of high volume, low-cost versions of existing vaccines.

To take stock of the health of today’s vaccination ecosystem and its ability to reliably and sustainably supply high-quality vaccines while investing in tomorrow’s needed innovation, Fondation Mérieux organized a conference entitled “Vaccination ecosystem health check: achieving impact today and sustainability for tomorrow” on January 19–21, 2015, in Annecy, France. Participants included representatives from international organizations [WHO, Gavi, international facility for the purchase of drugs against HIV/AIDS, Malaria and Tuberculosis (UNITAID), Médecins Sans Frontières (MSF), etc.] and industry.

To elicit more consideration of the vaccine ecosystem, a breakout session was held for participants in small working groups to discuss how to keep the vaccination ecosystem healthy.

This report summarizes selected issues discussed by participants, including the key findings and recommendations for future approaches to addressing this issue.

**Vaccination ecosystem**

The vaccine ecosystem involves a large number of actors (producers, purchasers, payers, supply side facilitators, program implementers, etc.) with mutual interactions (Fig. 1) [1]. Vaccine producers are conventionally divided into two groups: those investing large parts of their revenues in research and development (R&D) and those primarily involved in manufacturing and sales. The first group mainly consists of multinational firms based in the United States and Europe, even if emerging manufacturers from developing countries are scaling up. Governments, philanthropic organizations, WHO, and Gavi ensure vaccine purchasing, while the United Nations Children’s Fund (UNICEF) is the global lead for vaccine procurement.

The Gavi Alliance mainly ensures access to immunization in poor countries. Currently, Gavi supports routine vaccination programs (pentavalent, pneumococcal, yellow fever, etc.), vaccination campaigns (yellow fever, Meningococcal A, measles-rubella, Japanese encephalitis), stockpile for outbreak responses (yellow fever, meningitis, cholera) and malaria vaccine pilot, supply and procurement strategy. UNICEF works in partnership with governments, global partners, and a large number of suppliers. The continuous changes in both supply and demand creates a dynamic market that requires continuous monitoring and
management. Indeed, the annual vaccine procurement has increased significantly since 2000 due to the introduction of new vaccines. In 2014, UNICEF procured 2.7 billion doses of more than 40 vaccines for 100 countries at a value of $1.474 billion. Currently, the largest contributions come from industrialized countries, but emerging markets’ participation is increasing over time.

The participants attempted to analyze the health of vaccine eco-system in terms of coverage, demand, supply, and R&D.

**Global vaccine coverage, demand, and supply**

The establishment of the World Health Organization Expanded Program on Immunization (WHO-EPI) more than 40 years ago, adequate program design and implementation and international cooperation have led not only to increased vaccine coverage rates around the world, but also to reduced disease burden [2–4], and to smaller access inequities between low- and high-income countries even for new vaccines such as hepatitis B and pneumococcal vaccines. Despite these successes, large coverage gaps remain, which will need significant financial resources and political motivations to address. Indeed, the limited number of manufacturers and buyers in parallel to an increasing demand in terms of new vaccines introduced in the WHO-EPI especially in lower-income countries, could create a disconnect between demand and supply.

An important unaddressed challenge is to vaccinate the 20% of the world’s children born each year that do not receive even the most basic vaccinations. In 2011, the Global Vaccine Action Plan (GVAP) for the Decade of Vaccines (DoV) was created with the ambitions to close the equity gap in vaccine delivery and to unleash vaccines’ vast future potential. The new global vaccines and immunization framework provides space for all stakeholders to improve delivery, demand, and research. GVAP mid-point targets were 1) Diphtheria-Pertussis-Tetanus (DTP3) coverage >90% in all countries and >80% in every district by 2015, 2) polio transmission stopped by 2014, 3) maternal and neonatal tetanus eliminated by 2015, 4) measles eliminated in four regions by the end of 2015, 5) rubella eliminated in two regions by the end of 2015, and 6) introduction of one or more underutilized vaccines in low- or middle-income countries by 2015. An independent assessment performed by the Strategic Advisory Group of Experts on Immunization (SAGE) in 2014 expressed concerns about low implementation of GVAP as all targets except the last one were off track.

**Global vaccine research and development**

The vaccine industry is entering a period of uncertainty that threatens the new vaccine pipeline. Additional needs for basic science research; continuously rising manufacturing standards and regulatory requirements; the scientific challenge of developing vaccines for unmet needs (cytomegalovirus, HIV, tuberculosis, etc.); and increased cost, time, and risk of vaccine research and development driven by late-stage (phase 3) trials are among major contributing factors that limit the number of vaccines that a company is willing or able to develop to meet public health needs. One important result of this situation is that major companies are only interested in blockbusters. Therefore, main vaccine manufacturers do not consider many infections with somewhat restricted market size such as Lyme, cryptosporidium, and West Nile a top priority. Furthermore, the pressure to keep vaccine prices low, both in developed and developing countries, threatens to move manufacturing capability out of North America and Europe to reduce costs.

**Today’s vaccination ecosystem health status**

Today’s vaccine ecosystem is facing keys issues with regard to supply/distribution and cost/profitability asymmetry that risk slowing the global health of vaccine ecosystem. Indeed, a disconnect exists between the WHO global vaccine action plan (GVAP) and market shaping This could be due to overdependence on “price reduction” metrics and underdeveloped metrics for future innovation and supply security. Furthermore, cost/profitability asymmetries could provoke market exit and market failure when reinvestment is required. Several years of yellow fever vaccine shortage illustrates this situation well [5, 6]. New challenges related to population growth; increase in the number, doses, and cost of vaccines targeting a wider age group beyond that of infants; inadequate systems (trained human resources, supply chain, information system); vaccine supply and price (i.e., availability, financing, pricing, and procurement); and the goal of reaching the 20% of the world’s children born each year that are never (or incompletely) vaccinated due to political crisis, migration, failure of integration (i.e., missed opportunities), hesitancy, and refusal, further amplify the complexity of the vaccination ecosystem.

**Possible solution frameworks**

Possible solutions discussed during the conference for sustaining a healthy vaccination ecosystem are summarized in the following paragraphs.

**Global vaccine coverage, demand, and supply**

High-quality data are crucial to empower immunization program management, to increase vaccine uptake and to reach those children who are never vaccinated. Regular data review, data triangulation with other available sources, periodic data quality assessment, and training of
health care workers are examples of methods that could considerably improve data quality. Household surveys to measure immunization coverage are also needed to validate administrative data and provide additional information on missed opportunities and timely vaccination. Using traditional methods such as home-based vaccination records and new technologies such as modern Information, Communication and Technology (ICT) tools can also considerably improve data quality and thus contribute to improvement in coverage.

Another issue that can influence global vaccine coverage concerns the sustainability of financial support for Gavi–eligible graduating countries. Price-freezing for a period of five years is a possible solution, currently under evaluation, for these countries to sustain their expanded immunization programs without facing huge economic impact.

Weak immunization supply chain systems are another bottleneck to achieving immunization goals. Fortunately, key supply chain challenges have been diagnosed and their importance acknowledged. New technologies to reduce storage volume, expand the reach of cold chain to areas without reliable energy sources using solar equipment or long-lasting vaccine containers, provide new vaccine delivery models, allow combined vaccines and better schedules (number or timing of doses) are some technical solutions that exist and/or are in development and that could address vaccine supply challenges.

As described previously, the existing disconnects between demand and supplies are due to the limited number of manufacturers and buyers and the increasing demand in terms of vaccine products. Gavi adopted a supply and procurement strategic goal to shape the vaccine market by balancing supply and demand, ensuring security of supply, minimizing the cost of vaccines, and fostering development of appropriate and quality vaccines. So far, Gavi increased the number of vaccine suppliers from five in 2001 to 15 in 2014, including manufacturers from emerging markets. Other procurement strategies could further improve vaccine supply, including negotiation such as selective contracting/exclusive dealing and auctions.

**Global vaccine research and development**

Possible solutions for sustaining vaccine research and development and innovation are 1) incentives for industry to invest in new vaccines and improve old vaccines, 2) agreement between Food and drug administration/European medicine agency (FDA/EMA) to limit numbers needed for efficacy trials (phase 2B versus phase 3 trials), 3) increased interaction between high- and low-income countries to facilitate technology transfer, and 4) set-up of an international vaccine development fund that would support biotech escalating from lab to proof of concept and vaccine manufacturers developing vaccines for tropical and neglected diseases. Policies that make innovation and distribution reasonably profitable could also address these issues. Such policies include providing government supports for development and production, reducing uncertainty by establishing clear property rights, taxing negative spillovers, and subsidizing positive spillovers. Innovation must be profitable, but regulation to lower prices can slow innovation and diffusion by reducing return on investment. A price that is affordable to governments and donors and reasonably covers manufacturer’s minimum requirement could thus enhance vaccine R&D. Price discrimination, i.e., different prices for the same product in different settings (e.g., developed vs. developing countries), could also allow profitability to be maintained, thus generating more innovation. In low-income countries, differential patent rights, compulsory licenses, prizes, and advance market commitments to recommend a vaccine once licensed could also address supply and innovation.

Conditional licensure of vaccines as part of a system that would incorporate a requirement for rapid cycle and other real-time evaluations following introduction is another potential solution. Indeed, the cost and time of large routine safety trials prior to vaccine licensure are constantly increasing and could have a negative impact on the vaccine development pipeline without concomitant and dramatic increase in our ability to assess safety. The examples of Rotateq andRotarixshow that despite very large phase 3 clinical trials, increased risk of intussusception only became apparent and statistically significant in the post licensure period (Table 1).

Similarly, post-introduction data on pneumococcal conjugated vaccines (PCV) show that the vaccine had higher impact on the reduction of invasive pneumococcal diseases, otitis media, and all causes of pneumonia than what was reported in phase III clinical trials (Table 2).

Conditional licensure will lower the financial barriers to development of new vaccines and consequently allow a broader portfolio of vaccines to be developed.

**Valuing vaccination**

In recent years, a compelling line of inquiry has established the economic benefits of health, at both individual and aggregate levels. Most economic evaluations of vaccines focus on a narrow set of vaccination-mediated benefits (i.e., avoided medical costs and absenteeism) and fail to account for the role of vaccination as a driver

| Vaccine   | Risk of intussusception following rotavirus vaccination | Phase III Clinical Trial | Post introduction |
|-----------|--------------------------------------------------------|--------------------------|--------------------|
| Rotateq   | RR = 1.6 (95% CI: 0.4–6.4) [10]                        | RR = 9.9 (95% CI: 3.7–26.4) [11] |
| Rotarix   | RR = 0.86 (p = ns) [12]                               | RR = 6.8 (95% CI: 2.4–19.0) [11] |

RR Relative risk, CI Confidence interval, ns not statistically significant
Furthermore, reduction of the precautionary principle in
identified also several items to improve or add to ensure
as well as R&D (Additional file 1). The working group
system in terms of vaccine coverage, supply and demand
that could influence the sustainability of the vaccine eco-
allowed participants to discuss main topics that deserved
IPD 93.9% (95% CI: 79.6–98.5) [13] >99% [14]
Otitis media 7.0% (95% CI: 4.1–9.7) [13] 20% (95% CI: 4–34) [15]
All cause pneumonia 6% (95% CI: 1.5–11) [16] 39% (95% CI: 22–52) [17]
Cost-effectiveness US$80,000/QALY [18] US$75,000/QALY [19]

Table 2 Comparison of phase III clinical trials and post
marketing data on PCV efficacy

| Outcome               | Phase III Clinical | Post Introduction |
|-----------------------|-------------------|-------------------|
| IPD                   | 93.9% (95% CI: 79.6–98.5) [13] | >99% [14] |
| Otitis media          | 7.0% (95% CI: 4.1–9.7) [13] | 20% (95% CI: 4–34) [15] |
| All cause pneumonia   | 6% (95% CI: 1.5–11) [16] | 39% (95% CI: 22–52) [17] |
| Cost-effectiveness    | US$80,000/QALY [18] | US$75,000/QALY [19] |

| IPD Invasive pneumococcal diseases, CI Confidence interval, QALY Quality-adjusted life year

of wealth and its known impact on health, leading to po-
tentially sizable undervaluation of the true economic
value of vaccines. A broader perspective in economic
analysis considers other benefit categories including 1) outcome-related productivity gains, 2) behavior-related
productivity gains, 3) community externalities (i.e., herd
effect and prevention of antibiotic resistance), and 4) utilitarian value of health gains. Cost-effectiveness and
benefit-cost analyses are tools to assess the value of vac-
cination. The latter is more appropriate for economic
analysis because it looks at a range of health and non-
health-related outcomes that are expressed in terms of a
dollar value. The example of Hib vaccine in children
provided evidence of a benefit-cost ratio above 1 [7].
Another example is the case of dengue infection. By tak-
ing into account reduced spending on outbreak control,
averted losses in tourism flows, and avoided productivity
losses due to long-term dengue sequela, introducing den-
gue vaccine in national immunization programs in Brazil
would more than double the narrow benefit calculation,
allowing twofold return on the investment [8].

Similar conclusions can be drawn for human papilloma virus
(HPV) vaccination if the full benefits of vaccination are
captured [9].

Conceptualizing the full benefits of vaccination allows
better recognition of the value of vaccination as a driver of
both wealth and health. Monetizing the impact of
vaccination provides policymakers with sufficient infor-
mation to make well-informed decisions about including
other new vaccines in national immunization programs.

Outcomes of the workshops

Breakout sessions following the overall presentations on
the current status of today’s vaccination ecosystem
allowed participants to discuss main topics that deserved
more in-depth attention. Different factors were identified as drivers or barriers
that could influence the sustainability of the vaccine eco-
system in terms of vaccine coverage, supply and demand
as well as R&D (Additional file 1). The working group
identified also several items to improve or add to ensure
the health of the vaccination ecosystem (Additional file 2).
Furthermore, reduction of the precautionary principle in
government regulation and market failure could also con-
tribute to the health of the vaccination ecosystem.

Conclusions and recommendations

The panel concluded that despite the considerable pro-
gress achieved, introduction of new vaccines in LMICs,
sustained coverage with new and traditional vaccines,
and better performance of supply chains), today’s vaccin-
ation ecosystem faces several challenges that could
weaken it. These include small and decreasing numbers
of suppliers/manufacturing facilities; paucity of research-
driven companies; regulatory pressures; market un-
certainties (cost-effectiveness, price, higher demand and
supply); political prioritization (competing priorities or
distortion due to crisis, political instability); anti-vaccine
movements/complacency; and technological and pro-
grammatic issues (supply chain, cold chain custody,
health care worker education).

However, the panel identified several potential solutions.

Guaranteed return on investment for donors, govern-
ments, and global stakeholders; presence of multiple
effective suppliers to reduce monopolies and secure sup-
ply; financing for research and development; political
prioritization by raising awareness about needs; empower-
ment of developing country manufacturers (e.g., technol-
ogy transfer); and balance of public-private perspectives
for global public goods and distinction of the roles of
each sector could potentially positively affect the vaccination ecosystem.

In parallel, the current low-price-focused market shaping
could lead to critical asymmetry between cost and profit-
bility for Gavi–dedicated vaccines. This phenomenon is
apparent in the supply shortage for most Gavi vaccines,
exit of R&D producers from production to heritage vac-
cines, increased concentration of most vaccine production
by fewer producers, increased number of vaccines with just
one or two suppliers, and static or falling levels of vaccine
producers and R&D activity. Challenging vaccine prices is
complex. The need exists to collect more accurate data to
assess the full benefits of vaccines because we cannot chal-
allenge the cost without considering the whole benefits.

To summarize, the concept of an ecosystem is a useful
way of thinking about vaccines. A healthy ecosystem
should be able to maintain its organization and function
over time in the face of external stress. The supply issue
is a central aspect that requires much more work. Re-
search and development also face challenges. Prioritizing
a list of vaccine-preventable diseases to target and
matching it with R&D activities could optimize the lat-
ter, especially if a global development fund is in place.
Mechanisms such as regulatory reforms and technical
innovation to improve access to markets and shorten disruption periods could also contribute to the sustainability of the vaccination ecosystem. Our goal should be to investigate how we can best work together to ensure the sustainability of increasing global vaccination without damaging global vaccine production and/or R&D. A shared responsibility is needed to keep the vaccination ecosystem healthy.

Acknowledgements
The authors express their gratitude to all speakers who shared their findings. Thanks are also due to Cindy Grasso (meeting coordinator) and the staff of the Mérieux Foundation conference center for outstanding local organization. The organization of this meeting was made possible through support from Sanofi Pasteur.

List of speakers and chairs
Steven Black: USA | University of Cincinnati Children’s Hospital
Thomas Chérian: Switzerland | WHO
Kaitlyn Christenson: USA | PATH
Jennifer Cohn: Switzerland | Medecins Sans Frontieres Access Campaign
Heather Deehan: Denmark | UNICEF, Supply Division
James Droop: UK | Department for International Development
Awi Federgruen: USA | Colombia University
Martina Gaynor: USA | Carnegie Mellon University
Robert Harrison: UK | Liverpool School of Tropical Medicine
Suresh Jadhav: India | SERUM INSTITUTE OF INDIA LTD.
Ross Leach: UK | Department for International Development
Henny Miller: USA | Hoover Institution/Stanford University
Julien Potet: USA | Medecins Sans Frontieres Access Campaign
Anthony Sa: USA | Duke University
Brenda Waning: Switzerland | UNITAID/WHO
Greg Widmyer: USA | Bill and Melinda Gates Foundation

Funding
The publication of this article was founded by the Mérieux Foundation (Lyon-France).

Authors’ contributions
DB, ST, JL and VP set-up the program. MSE drafted the first version of the manuscript. All authors commented and reviewed the draft, read and approved the final manuscript.

Competing interests
MW was employee of Sanofi Pasteur at the time of the meeting. Other authors declare that they have no conflicts of interest to report.

Author details
1Groupement Hospitalier Edouard Herriot, Service d’Hygiène, Epidmiologie et Prévention, Bâtiment 1, 5, place d’Arsonval, 69437 Lyon, Cedex 03, France. 2Harvard T.H. Chan School of Public Health, 665 Huntington Avenue, Boston, MA 02215, USA. 3University of Pennsylvania and Vaxconsult, LLC, Philadelphia, USA. 4Fondation Mérieux, 17 rue Bourgelat, 69002 Lyon, France. 5Valera, Cambridge, MA 02141, USA.

Published: 27 January 2017

References
1. Watson M, Paron de Goer E. Are good intentions putting the vaccination ecosystem at risk? Hum Vacc Immunother. 2016;12(9):2469–74. doi:10.1080/21645515.2016.1172162.
2. Global progress towards regional measles elimination, worldwide, 2000–2013. Wkly Epidemiol Rec. 2014;89(46):509–516.
3. Oluwalana C, Howie SR, Secka O, Iedch RC, Ebruke B, Sambou S, et al. Incidence of Haemophilus influenzae type b disease in The Gambia 14 years after introduction of routine Haemophilus influenzae type b conjugate vaccine immunization. J Pediatr. 2013;163(1 Suppl):S4–7. doi:10.1016/j.peds.2013.03.023.
4. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, Esparza-Aguilar M, Johnson B, Gomez-Altamirano CM, et al. Effect of rotavirus vaccination on death from childhood diarrhoea in Mexico. N Engl J Med. 2010;362(4):299–305. doi:10.1056/NEJMoa0905211.
5. World Health Organization (WHO). Yellow fever factsheet. In World Health Organization’s online media center. 2014. http://www.who.int/mediacentre/factsheets/fs100/en/. Accessed 7 Oct 2016.
6. UNICEF. Yellow fever vaccine: current outlook, UNICEF Supply division. 2013. http://www.unicef.org/supply/files/Yellow_Fever_Vaccine_Current_Outlook_Nov_2013.pdf. Accessed 7 Oct 2016.
7. Bärnighausen T, Bloom DE, Canning D, Friedman A, Levine OS, O’Brien J, et al. Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine. Vaccine. 2011;29(13):2371–80. doi:10.1016/j.vaccine.2010.11.090.
8. Bärnighausen T, Bloom DE, Callejo ET, O’Brien J.C. Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus. Clin Microbiol Infect. 2012;18 Suppl 5:S70–6. doi:10.1111/j.1469-0691.2012.03977.x.
9. Bärnighausen T, Bloom DE, Callejo ET, O’Brien J. Valuing the broader benefits of dengue vaccination, with a preliminary application to Brazil. Semin Immunol. 2013;25(2):104–13. doi:10.1016/j.seminimun.2013.04.010.
10. Verkait T, Karvonen AV, Majuri J, Zeng SQ, Pang XL, Kohberger R, et al. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J Infect Dis. 2006;194(3):370–6.
11. Caffin JB, Macartney KK, Lee KU, Quinn HE, Butterly J, Lopert R, et al. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia’s National Immunization Program. Clin Infect Dis. 2013;57(10):1427–34. doi:10.1093/cid/cit520.
12. Ward RL, Bernstein DI. Rotarix: a rotavirus vaccine for the world. Clin Infect Dis. 2009;48(2):222–8. doi:10.1086/595702.
13. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2006;25(6):494–501.
14. Pneumococcal disease: Surveillance and reporting. https://www.cdc.gov/vaccines/pubs/sun-manual/chpt11-pneumo.html. Accessed 7 Oct 2016.
15. Grivelja CG, Poehling KA, Nuorti JP, Zhu Y, Martin SW, Edwards KM, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics. 2006;118(3):865–73.
16. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21(9):810–5.
17. Grivelja CG, Nuorti JP, Arboagost PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369(9568):79–86.
18. Lieu TA, Ray GT, Black SB, Butler JC, Klein JO, Breiman RF, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2002;288(1):1460–8.
19. Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J. 2006;25(6):494–501.